Pharming Group N.V. announces the agenda for its Capital Markets Briefing to be held from 08:00 to 10:30 EST/14:00-16:30 CET on 21 June 2018 in New York, NY, and through a live webcast.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.

Pharming Group N.V. presents its (unaudited) financial report for the quarter ended 31 March 2018.

Pharming Group N.V., the Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, announces publication of its 2017 annual report and issues an invitation to its Annual General Meeting for all shareholders.

Pharming Group N.V. today announced that it has been included in the Euronext Amsterdam SmallCap-index (AScX). On entry into the AScX, Pharming has become one of the larger index members.

Pharming Group N.V. today announced that during the period of 7 to 9 March, it has issued a total of 6,315,235 new shares following the exercise of warrants representing a total of 9,174,372 shares.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended 31 December 2017.

Pharming Group N.V. today announced that it has issued a total of 25,441,901 new shares and €1.9 million of cash to redeem €7.7 million of the Ordinary Convertible Bonds (“Bonds”).

Pharming Group N.V. today announced that it has issued a total of 10,563,380 new shares from within the amount allocated to conversion of the Ordinary Convertible Bonds (the “Bonds”) to redeem €3.0 million of the Bonds being converted by their holders, thereby reducing the outstanding amount of the Bonds to €8.5 million.

Pharming Group N.V., the Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, presents its (unaudited) financial report for the first nine months and the third quarter ended 30 September 2017.